In the randomised, phase 3 ENDEAVOR trial in patients with relapsed or refractory multiple myeloma, we showed that treatment with carfilzomib and dexamethasone compared with bortezomib and dexamethasone significantly improved progression-free survival (18·7 months with carfilzomib vs 9·4 months with bortezomib; hazard ratio [HR] 0·53 [95% CI 0·44–0·65]; p<0·0001) and overall survival (47·6 vs 40·0 months; HR 0·79 [0·65–0·96], p=0·010).^1,2 ENDEAVOR was the first head-to-head study of two different proteasome inhibitors in relapsed or refractory multiple myeloma, and these results established the combination of carfilzomib administered at 56 mg/m² twice weekly with dexamethasone as a new standard of care in this disease setting.

中文翻译：

---

卡非佐米用于复发性或难治性多发性骨髓瘤–作者的回复

在患有复发的或难治性多发性骨髓瘤的随机，相位3 ENDEAVOR试验中，我们显示出与卡非佐米和地塞米松在治疗与硼替佐米和地塞米松显著改善无进展生存期（18相比·7个月与卡非佐米VS 9·4个月与硼替佐米；危险比[HR] 0·53 [95％CI 0·44-0·65]； p <0·0001）和总生存期（47·6 vs 40·0个月； HR 0·79 [0·65– 0·96]，p = 0·010）。^1,2 ENDEAVOR是针对复发或难治性多发性骨髓瘤中两种不同蛋白酶体抑制剂的首次头对头研究，这些结果确定了每周两次以56 mg / m ^2的剂量联合使用卡非佐米与地塞米松作为新的护理标准在这种疾病的情况下。